anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypertension is a common but frequently overlooked and underreported adverse effect of erythropoietin (EPO) therapy. Recent trials have noted substantial cardiovascular risks associated with normalization of hemoglobin. The risk of strokes is strongly related to poorly controlled hypertension. Blood pressure was not measured the way it usually is in hypertension trials, so the investigators cannot be completely confident that the risk of strokes in this large randomized trial was not related to EPO-induced hypertension. New therapies, such as hypoxia-inducible factor (HIF) stabilizers are on the horizon but it remains to be seen whether these new drugs would have a lower or a higher risk for hypertension compared to EPO. Accordingly, understanding the mechanism of EPO-induced hypertension is urgent. The investigators hypothesize that compared to untreated controls, EPO therapy in anemic patients with chronic kidney disease (CKD) will raise diastolic blood pressure. The magnitude of increase in diastolic BP at 12 weeks after treatment will be related to endothelial dysfunction and worsening of endothelial function from baseline to 4 weeks. If the investigators understood the time course, the magnitude, and the mechanisms of EPO-induced hypertension (EIH) the investigators will better be able to design studies to compare the vascular effects of EPO and HIF stabilizers in the future. Thus, this study has the potential of improving the investigators' understanding of a common side effect of EPO by precisely quantifying the magnitude of BP change, its effects on endothelial function, and discovering the biomarkers of these adverse effects. Thus, the investigators can in the future robustly compare these effects of EPO with HIF stabilizers. This study is innovative because it will focus on the potential mechanisms by which EPO induces an increase in BP. The time-course and magnitude of change in BP will be assessed using the gold-standard measurement of 24 hour ambulatory BP recordings. The more frequent clinic BP recordings using validated methods will better allow us to track changes in BP over time. The investigators' lab is uniquely qualified to carry out these experiments due to a large experience with such types of studies. The investigators will examine endothelial function using a reference method -- that of flow-mediated dilatation -- which is established in the investigators' laboratory. The investigators will directly test the hypothesis whether endothelial function is responsible for the BP increase.
Methods and apparatuses (e.g., tracking system, tracking devices, etc.) for tracking a subject to prevent elopement. The methods and apparatuses described herein may be used to prevent elopement from health care environments. The methods and apparatuses may be specifically configured to provide energy and cost efficient mechanisms to prevent elopement and to track subjects. For example, these methods and apparatuses may monitor, using a wearable tracking device, low-energy sensor data and determining whether the sensor data exceeds a threshold. If the sensor data exceeds a threshold, then the tracking device can turn on scanning for a wireless signals associated with a known location, and/or activate a location-determining subsystem of the tracking device and transmit location information and/or an alert to a remote processor.
Occupational therapy applications were carried out 40 minutes, twice a week (one individual session and one group intervention session) and total of 8 weeks. In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
Phase 2: This intervention will serve as an augmentation arm for participants who do not respond to either MBP or VCP after 6 weeks of care. Like the Premium Plan, participants will have access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist.
The invention relates to a Chinese medicine preparation, in particular to a heat-clearing stranguria-treating drug used to cure heat stranguria caused by downward flow of damp and heat. The heat-clearing stranguria-treating drug is prepared by active ingredients and pharmaceutically commonly used excipient or auxiliary materials. The active ingredients are prepared by the following raw material medicines in parts by weight: 24-36 parts of creeping rostellularia herb, 2-4 parts of lightyellow sophora root, 7-11 parts of cogongrass rhizome and 0.5-1.5 parts of borax. The heat-clearing stranguria-treating drug has the functions of heat clearing, dampness removing and stranguria treating and can be used to cure heat stranguria caused by downward flow of damp and heat reflected by symptoms such as frequent urination, urethra pricking, nebular urine, dry throat with bitter taste and the like, and acute lower urinary tract infections with the symptoms. According to 60 clinical observation cases and 30 urine retention clearing tablet control groups, the curative rate of a treatment group is 31.7 percent and the total effectiveness is 88.3 percent; and the curative rate of the urine retention clearing tablet control groups is 16.7 percent and the total effectiveness is 66.67 percent. The heat-clearing stranguria-treating drug has the advantages that the curative effect is good, the safety and the reliability are high, no obvious toxic side effect is caused, the curative effect is superior to the curative effect of the similar control products and certain popularization and application value exists.
Semaphorin-plexin signaling plays a major role in the tumor microenvironment (TME). In particular, Semaphorin 4D (SEMA4D) has been shown to promote tumor growth and metastasis; however, the role of its high-affinity receptor Plexin-B1 (PLXNB1), which is expressed in the TME, is poorly understood. In this study, we directly targeted PLXNB1 in the TME of triple-negative murine breast carcinoma to elucidate its relevance in cancer progression. We found that primary tumor growth and metastatic dissemination were strongly reduced in PLXNB1-deficient mice, which showed longer survival. PLXNB1 loss in the TME induced a switch in the polarization of tumor-associated macrophages (TAM) toward a pro-inflammatory M1 phenotype and enhanced the infiltration of CD8+ T lymphocytes both in primary tumors and in distant metastases. Moreover, PLXNB1 deficiency promoted a shift in the Th1/Th2 balance of the T-cell population and an antitumor gene signature, with the upregulation of Icos, Perforin-1, Stat3, and Ccl5 in tumor-infiltrating lymphocytes (TILs). We thus tested the translational relevance of TME reprogramming driven by PLXNB1 inactivation for responsiveness to immunotherapy. Indeed, in the absence of PLXNB1, the efficacy of anti-PD-1 blockade was strongly enhanced, efficiently reducing tumor growth and distant metastasis. Consistent with this, pharmacological PLXNB1 blockade by systemic treatment with a specific inhibitor significantly hampered breast cancer growth and enhanced the antitumor activity of the anti-PD-1 treatment in a preclinical model. Altogether, these data indicate that PLXNB1 signaling controls the antitumor immune response in the TME and highlight this receptor as a promising immune therapeutic target for metastatic breast cancers.
PURPOSE:To obtain an enzyme useful for drugs, cosmetics, etc., having optimum pH in the vicinity of neutrality, wide activity from an acidic range to an alkali range and activity against natural ceramide fractions. CONSTITUTION:Ceramidase B. Action: hydrolyzing natural ceramide, palmitoyl sphingosine, oleoyl sphingosine and linoleyl sphingosine. Substrate specificity: showing strong activity against palmitoyl sphingosine, oleoyl sphingosine, linoleyl sphingosine and total natural ceramide, especially strong activity against ceramide.type I, II, IV and V. Optimum pH: about 9. Stable pH range: 5-10. Proper temperature of action: 15-45 deg.C. Optimum temperature: 30-40 deg.C. Deactivation condition by temperature: completely deactivated by retaining at pH7.4 at 60 deg.C for 60 minutes. Molecular weight: 140,000+ or -25,000. The enzyme, for example, is obtained by extracting epidermis of guinea pig with an aqueous solvent and purifying the extracted solution by a well-known method such as salting-out, ultrafiltration, adsorption column chromatography, etc.
Stenting has reduced the need of revascularization procedures in stable CAD and ACS as compared to POBA. The use of stents is favored in stable CAD and in ACS according the the present ESC guidelines. However, especially in patients on warfarin or in patients at a high bleeding risk, stenting (and the use of DES in particular) is not recommended because of the longer DAPT required. In these patients, BMS may be used to shorten the duration of DAPT. However, there are problems associated with the treatment using BMS. First of all, a considerable high rate of restenosis is associated with stenting with BMS. Furthermore, stenting may be complicated by the "no-reflow" phenomenon, a coronary dissection or the closure of side branch during the treatment of bifurcation lesions. Implantation of a stent also exposes the patient to stent thrombosis. In contrast, these problems may be avoided by the use of DEB with the provisional BMS strategy.

The use of DEB has already been established in the treatment of ISR. Despite the lack of data of RCTs, DEB is already widely used in a variety of clinical situations in which stenting is not desirable. These situations include for example anticoagulation treatment, a high bleeding risk, poor compliance regarding medication, small vessels, bifurcation lesions, long and/or calcified lesions, in case of a marked variation in the vessel reference caliber, in long lesions and in patients with ACS. The all-comer registry data is promising but only hypothesis generating. Thus, it would be very important and ethical to test the efficacy of DEB in a wider patient population in a randomized controlled study.

Our hypothesis is that DEB is non-inferior to BMS in the treatment of stable CAD or in ACS (UAP or NSTEMI) in patients on anticoagulation medication or otherwise having a high bleeding risk. Our study sheds light on the use of DEB in PCI of this challenging patient population. In most previous studies, BMS has been routinely added to the DEB treatment. This strategy seems not to yield any benefit but in contrast causes an increased risk of restenosis as compared to the DEB only strategy with provisional stenting. Finally, the current data on the use of DEB in patients with ACS is scarce and our study gives significant information also on this important issue.
Nicotine smoking contributes to many preventable disabilities, diseases and deaths. Targeting nicotine reward and withdrawal is a basis for the majority of smoking cessation pharmacotherapies. Due to the emergence of interest in 5-HT2A receptor modulators for numerous psychiatric disorders, we investigated the effect of nelotanserin, a 5-HT2A receptor inverse agonist, on nicotine reward and withdrawal in ICR mice. In nicotine-dependent mice, nelotanserin dose-dependently reduced somatic signs of nicotine withdrawal and thermal hyperalgesia as measured in the hot plate test. However, nelotanserin had no effect on anxiety-like behavior and failed to reduce nicotine reward as measured in the conditioned place preference test. Our results suggest that inverse agonism of the 5-HT2A receptor may be a feasible novel mechanism for smoking cessation by reducing both physical withdrawal and thermal hyperalgesia associated with nicotine abstinence but may require complementary pharmacotherapies targeting affective and reward-associated decrements to improve cessation outcomes.
PURPOSE: Patchable pas containing yellow soil that can alleviate toxicity is provided. The yellow soil is abundant in a variety of minerals, and applied to a patchable pas in the form of fine powder. CONSTITUTION: To achieve the beforementioned purpose, firstly a predetermined amount of yellow soil is collected, screened, and disinfected to remove harmful factors. And then, the processed yellow soil is put in a container which is full of water. As time goes by, the mixture consisted of water and yellow soil is separated into two layers, i.e sediments precipitates at the bottom part and yellow soil solution is located in the upper part. The yellow soil powder is applied as an ingredient of a patchable pas in the preparation process of sorts of patchable pas.
Zinc Sulfate Injection is supplied as a pharmacy bulk package for admixing use only. It is not for direct intravenous infusion. Prior to administration, Zinc Sulfate Injection must be transferred to a separate parenteral nutrition container, diluted and used as an admixture in parenteral nutrition solutions. 

The final parenteral nutrition solution is for intravenous infusion into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsmol/L or greater must be infused through a central catheter [see Warnings and Precautions (5.2)].
A process is disclosed for enabling an operator to exercise on an exercise device. The process includes measuring a range of movement of the operator during exercising on the exercise device for generating an electronic range of movement data. A strength is measured of the operator during exercising on the exercise device for generating an electronic strength data. An electronic program is designed based on the electronic range of movement data and the electronic strength data. The electronic program is stored in an electronic media. The electronic program is displayed as a moving scale on a screen for instructing the operator to exercise at the same rate as the moving scale to complete the exercise in a timely and controlled matter.
Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
Participants receive counseling over the phone to help them quit smoking and learn about lung cancer screening over 15-20 minutes for 6-8 sessions over 8 weeks. Participants may also receive nicotine patches.
Participants will receive a low dose of ASP2802 on Day 0 of cycle 1. Each participant will then receive up to 2 doses of MA-20 booster in each 28-day cycle.
Techniques include receiving a treatment plan for a subject, including a body outline, a position on a couch, and, for each gantry angle, a couch angle an isocenter and target volumes to which a radiation source is directed. A perspective transform matrix is based on projected coordinates of reference points from a digital image projector onto each different plane perpendicular to a beam from the radiation source at different distances. Two-dimensional spot positions for a gantry and couch angle are determined based on the treatment plan. A group of spot positions are determined based on a common distance from the radiation source to the body outline. Illuminated spots on a projection image are determined based on the group and the perspective transform matrix closest to the common distance. The projection image is projected from the image projector onto the subject on the couch.
OBJECTIVES: This study aimed to identify the clusters of patients with different developmental trajectories of pain and disability after anterior cervical decompression and fusion (ACDF).
METHODS: Group-based trajectory analysis among 318 patients undergoing the ACDF.
RESULTS: Three developmental trajectories of disability were identified: "Steadily good functioning," "Improved functioning," and "Steadily poor functioning." Three developmental trajectories of neck pain were identified: "Worsened pain," "Pain relief," and "Steadily severe pain." Two developmental trajectories of arm pain were identified: "Decreased arm pain" and "Severe arm pain with only short-term relief." No associations were found between sex, preoperative pain duration, or body weight and probability to be classified into a particular disability trajectory group. Female sex (relative risk ratio (RRR) 1.78) and longer history of preoperative pain (RRR 2.31-2.68) increased the probability to be classified into a group with steadily severe neck pain. Longer history of preoperative pain increased the probability to be classified into group with severe arm pain with only short-term pain relief (RRR 2.68).
CONCLUSION: After the ACDF, dissimilar developmental trajectories of pain and disability were identified between the patient clusters. While sex, preoperative pain duration, and body weight were not associated with differences in improvement in disability level, female sex and longer duration of preoperative pain were correlated with more severe neck and arm pain after surgery.
Relaxation treatment (RT) is applied additional to standard physiotherapy treatment. RT includes 8 sessions (2 times a day, for four days after surgery) of relaxation exercises.
This retrospective cohort study identifies differences between rates of selected mental illnesses and sleep disorders according to eight gynecological problems. Analyses utilize medical claims data for adult employees of a large corporation during 2017-2021. Women with a gynecological problem (most notably pain, endometriosis, pelvic inflammation and bleeding) are significantly more likely to experience mental illness. Several gynecological problems are also significantly associated with sleep disorders. Women with a gynecological problem (vs. none) are 50% more likely to have a mental health problem and 44% more likely to have a sleep disorder after adjusting for age, marital status, dependent children and year. The largest differences between higher (%) mental illness and sleep disorders appear for hyperplasia (6% vs. 45%), cancer (11% vs. 68%), pelvic inflammation (46% vs. 79%) and pain (79% vs. 43%), respectively. On the other hand, the rate of having one or more gynecological problems ranges from 7.1% for women with no mental illness or sleep disorder to 20.6% for women with schizophrenia. Understanding the association between gynecological problems, mental illness and sleep disorders can help clinicians more effectively identify and treat patients.
A method and a system for providing bed availability information via a computer network are provided. A healthcare facility, such as a nursing home, a retirement home or any other type of healthcare or extended care resource, may provide bed availability and/or service information and other types of information to a database on a computer network whereby users of the computer network may access the information within the database. The hospital and/or other healthcare facility may create a transfer request form for discharge of a patient to an extended care facility. The transfer request form containing patient medical information and/or patient treatment information is reviewed by an agent. The agent makes a decision whether to approve or reject the transfer request. Further, a patient interview may be scheduled by the agent prior to making the decision. Notifications are sent to the parties involved with the discharge of the patient to the healthcare facility notifying the parties of the decision of the agent. The transfer request form may be created on-line via the computer network and/or may be reviewed by the agent on-line. The agent may make a decision to approve or to reject the transfer request on-line. In addition, the agent may schedule the patient interview and/or send notifications to the parties on-line.
A method and apparatus for inactivating contaminants, particularly nonenveloped viruses, in blood products without the need for quenchers in the blood products. The blood product is flowed through a flow meter at a controlled flow rate and subjected to type C ultraviolet radiation, where the irradiation dose received by the blood product is less than 640 joules/m 2 . The blood product does not contain quenchers when being irradiated, and the blood product retains more than 85% of its Factor VIII activity after being subjected to the radiation. The produced blood product is free of viruses and quenchers, avoiding potential toxicity due to the quenchers. The apparatus includes a source of UVC light, a quartz tube containing the blood product while it is exposed to the UVC light, a flow meter for controlling the flow rate of the blood product to be treated, and a pump. The UV light preferably emits light at 254 nm.
In Part 1, the first cohort will receive JNJ-64457107 at a starting dose of 75 microgram per kilogram (mcg/kg). The proposed treatment schedule is intravenous (IV) dosing every 14 days. JNJ-64457107 doses will be escalated following a modified Continual Reassessment Method (mCRM); the JNJ-64457107 dose will be increased by not more than half-logarithmical (3.2-fold) dose increments. Dose escalation will continue until the maximum tolerated dose (MTD) and/or RP2D of JNJ-64457107 are defined or the maximum-administered dose (MAD) has been reached. In Part 2, subjects will receive JNJ-64457107 at the RP2D and regimen determined in Part 1.
Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel compounds of the general formula (I)   where A means  ,  ; X means O; Y means O or S; G and D mean independently nitrogen or carbon atom; E means nitrogen atom or C-R 4  under condition that one of G, D or E, not above, means nitrogen atom; R 2  means hydrogen or fluorine atom; R 3  means hydrogen, halogen atom, C 1 -C 3 -alkyl, -OR 5 , -CN; or R 2  and R 3  or R 3  and R 4  can mean in common the condensed phenyl ring; R 5  means hydrogen atom or C 1 -C 3 -alkyl; or their enantiomers or pharmaceutically acceptable salts. The above indicated compounds are ligands with the strong effect for nicotine receptors of acetylcholine and can be used for treatment or prophylaxis of psychotic disorders and damages with decreased mental activity. Invention describes also methods of synthesis of these compounds, pharmaceutical composition and intermediate compounds. EFFECT: new compounds indicated above, improved methods of synthesis, valuable medicinal properties. 13 cl, 7 ex